Dapagliflozin, an SGLT2 inhibitor, for diabetes.

Share

First published in The Lancet on 2010 Jun.
Lancet. 2010 Jun 26;375(9733):2196-8. doi: 10.1016/S0140-6736(10)60749-0.

Authors: Hanefeld M, Forst T

Abstract

Comment on

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. [Lancet. 2010]
 
 

Read more

Download full article as Pdf file:

Pdf File